Patients with stage IV or unresectable not irradiable stage III NSCLC will be registered at the time receiving immunotherapy alone or in combination with chemotherapy.
When IO is stopped, reason for cessation and further treatment will be recorded.
Secondary endpoints are survival after IO cessation, activity of first salvage therapy, disease-free survival after IO cessation in patients receiving no further treatment.
Patients will be centrally registered at the ELCWP headquarter (Institut Jules Bordet, Brussels, Belgium).
How understandable was the trial content above?
Hard to understand
Easy to understand
